RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $119 to $117.
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $119 to $117.